2024
Projected health and economic effects of a pan-tuberculosis treatment regimen: a modelling study
Ryckman T, McQuaid C, Cohen T, Menzies N, Kendall E. Projected health and economic effects of a pan-tuberculosis treatment regimen: a modelling study. The Lancet Global Health 2024, 12: e1629-e1637. PMID: 39159654, PMCID: PMC11413512, DOI: 10.1016/s2214-109x(24)00284-5.Peer-Reviewed Original ResearchStandard of careInitial treatment attemptNewly diagnosed tuberculosis patientsTuberculosis burdenTreatment attemptDrug susceptibility testingProportion of patientsMechanisms of benefitNon-drug costsRifampicin susceptibilityTreatment discontinuationIncremental curingSusceptibility testingDrug susceptibilityRegimen developmentTreatment regimenTuberculosis patientsRegimenRegimensTuberculosis treatmentInjection regimensTuberculosis diagnosisRegimen assignmentsNon-adherenceSimulated cohort
2022
Budget impact of next-generation sequencing for diagnosis of TB drug resistance in Moldova
Cates L, Codreanu A, Ciobanu N, Fosburgh H, Allender C, Centner H, Engelthaler D, Crudu V, Cohen T, Menzies N. Budget impact of next-generation sequencing for diagnosis of TB drug resistance in Moldova. The International Journal Of Tuberculosis And Lung Disease 2022, 26: 963-969. PMID: 36163669, DOI: 10.5588/ijtld.22.0104.Peer-Reviewed Original ResearchConceptsPhenotypic drug susceptibility testingConventional phenotypic drug susceptibility testingTB drug resistanceDrug resistanceNext-generation sequencingTB treatment regimensNational TB ProgrammeDrug resistance testingMTB/RIFDrug susceptibility testingBudget impact analysisMajority of costsFeasibility of NGSTB programsTreatment regimensBudget impactSusceptibility testingRoutine useResistance testingStudy periodTesting volumeA crowd of BashTheBug volunteers reproducibly and accurately measure the minimum inhibitory concentrations of 13 antitubercular drugs from photographs of 96-well broth microdilution plates
Fowler P, Wright C, Spiers H, Zhu T, Baeten E, Hoosdally S, Cruz A, Roohi A, Kouchaki S, Walker T, Peto T, Miller G, Lintott C, Clifton D, Crook D, Walker A, Barilar I, Battaglia S, Borroni E, Brandao A, Brankin A, Cabibbe A, Carter J, Cirillo D, Claxton P, Clifton D, Cohen T, Coronel J, Crook D, Earle S, Escuyer V, Ferrazoli L, Fowler P, Gao G, Gardy J, Gharbia S, Ghisi K, Ghodousi A, Cruz A, Grazian C, Guthrie J, He W, Hoffmann H, Hoosdally S, Hunt M, Iqbal Z, Ismail N, Jarrett L, Joseph L, Jou R, Kambli P, Knaggs J, Koch A, Kohlerschmidt D, Kouchaki S, Lachapelle A, Lalvani A, Lapierre S, Laurenson I, Letcher B, Lin W, Liu C, Liu D, Malone K, Mandal A, Matias D, Meintjes G, Mendes F, Merker M, Mihalic M, Millard J, Miotto P, Mistry N, Moore D, Dreyer V, Chetty D, Musser K, Ngcamu D, Nhung H, Grandjean L, Nilgiriwala K, Nimmo C, Okozi N, Oliveira R, Omar S, Paton N, Peto T, Pinhata J, Plesnik S, Puyen Z, Rabodoarivelo M, Rakotosamimanana N, Rancoita P, Rathod P, Robinson E, Rodger G, Rodrigues C, Rodwell T, Roohi A, Santos-Lazaro D, Shah S, Kohl T, Smith G, Solano W, Spitaleri A, Supply P, Steyn A, Surve U, Tahseen S, Thuong N, Thwaites G, Todt K, Trovato A, Utpatel C, Van Rie A, Vijay S, Walker T, Walker A, Warren R, Werngren J, Groenheit R, Wijkander M, Wilkinson R, Wilson D, Wintringer P, Xiao Y, Yang Y, Yanlin Z, Yao S, Zhu B, Niemann S, O'Donnell M. A crowd of BashTheBug volunteers reproducibly and accurately measure the minimum inhibitory concentrations of 13 antitubercular drugs from photographs of 96-well broth microdilution plates. ELife 2022, 11: e75046. PMID: 35588296, PMCID: PMC9286738, DOI: 10.7554/elife.75046.Peer-Reviewed Original ResearchConceptsMinimum inhibitory concentrationIncreasing prevalence of resistanceBroth microdilution platesAntibiotic susceptibility testingPrevalence of resistanceInhibitory concentrationPanel of antibioticsClinical samplesSusceptibility testingMicrodilution platesDilution platingTreatment outcomesIncreased prevalenceAntitubercular drugsAntibioticsInhibited growthDrugCitizen science platformRespiratory diseaseLaboratory scientistsVolunteersPre-determined concentrationsThe 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis
Walker T, Miotto P, Köser C, Fowler P, Knaggs J, Iqbal Z, Hunt M, Chindelevitch L, Farhat M, Cirillo D, Comas I, Posey J, Omar S, Peto T, Suresh A, Uplekar S, Laurent S, Colman R, Nathanson C, Zignol M, Walker A, Crook D, Ismail N, Rodwell T, Consortium T, Walker A, Steyn A, Lalvani A, Baulard A, Christoffels A, Mendoza-Ticona A, Trovato A, Skrahina A, Lachapelle A, Brankin A, Piatek A, Cruz A, Koch A, Cabibbe A, Spitaleri A, Brandao A, Chaiprasert A, Suresh A, Barbova A, Van Rie A, Ghodousi A, Bainomugisa A, Mandal A, Roohi A, Javid B, Zhu B, Letcher B, Rodrigues C, Nimmo C, NATHANSON C, Duncan C, Coulter C, Utpatel C, Liu C, Grazian C, Kong C, Köser C, Wilson D, Cirillo D, Matias D, Jorgensen D, Zimenkov D, Chetty D, Moore D, Clifton D, Crook D, van Soolingen D, Liu D, Kohlerschmidt D, Barreira D, Ngcamu D, Lazaro E, Kelly E, Borroni E, Roycroft E, Andre E, Böttger E, Robinson E, Menardo F, Mendes F, Jamieson F, Coll F, Gao G, Kasule G, Rossolini G, Rodger G, Smith E, Meintjes G, Thwaites G, Hoffmann H, Albert H, Cox H, Laurenson I, Comas I, Arandjelovic I, Barilar I, Robledo J, Millard J, Johnston J, Posey J, Andrews J, Knaggs J, Gardy J, Guthrie J, Taylor J, Werngren J, Metcalfe J, Coronel J, Shea J, Carter J, Pinhata J, Kus J, Todt K, Holt K, Nilgiriwala K, Ghisi K, Malone K, Faksri K, Musser K, Joseph L, Rigouts L, Chindelevitch L, Jarrett L, Grandjean L, Ferrazoli L, Rodrigues M, Farhat M, Schito M, Fitzgibbon M, Loembé M, Wijkander M, Ballif M, Rabodoarivelo M, Mihalic M, WILCOX M, Hunt M, ZIGNOL M, Merker M, Egger M, O'Donnell M, Caws M, Wu M, Whitfield M, Inouye M, Mansjö M, Thi M, Joloba M, Kamal S, Okozi N, ISMAIL N, Mistry N, Hoang N, Rakotosamimanana N, Paton N, Rancoita P, Miotto P, Lapierre P, Hall P, Tang P, Claxton P, Wintringer P, Keller P, Thai P, Fowler P, Supply P, Srilohasin P, Suriyaphol P, Rathod P, Kambli P, Groenheit R, Colman R, Ong R, Warren R, Wilkinson R, Diel R, Oliveira R, Khot R, Jou R, Tahseen S, Laurent S, Gharbia S, Kouchaki S, Shah S, Plesnik S, Earle S, Dunstan S, Hoosdally S, Mitarai S, Gagneux S, Omar S, Yao S, Lapierre S, Battaglia S, Niemann S, Pandey S, Uplekar S, Halse T, Cohen T, Cortes T, Prammananan T, Kohl T, Thuong N, Teo T, Peto T, Rodwell T, William T, Walker T, Rogers T, Surve U, Mathys V, Furió V, Cook V, Vijay S, Escuyer V, Dreyer V, Sintchenko V, Saphonn V, Solano W, Lin W, van Gemert W, He W, Yang Y, Zhao Y, Qin Y, Xiao Y, Hasan Z, Iqbal Z, Puyen Z. The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis. The Lancet Microbe 2022, 3: e265-e273. PMID: 35373160, PMCID: PMC7612554, DOI: 10.1016/s2666-5247(21)00301-3.Peer-Reviewed Original ResearchConceptsConsistent with susceptibilityAssociated with resistancePhenotypic resistanceDrug susceptibility testingSusceptibility testingPositive predictive valueAssociated with phenotypic resistanceWhole-genome sequencingPrevalence of phenotypic resistanceMolecular diagnosticsDrug susceptibility testing dataUniversal drug susceptibility testingMutations associated with drug resistanceOdds ratioSusceptibility testing dataDrug resistance predictionImplementation of molecular diagnosticsBinary phenotypesPredictive valueGene approachMTBC isolatesUnique mutationsFisher's exact testAnti-tuberculosis drugsGenotype analysis
2016
Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective
Kendall EA, Cohen T, Mitnick CD, Dowdy DW. Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective. International Journal Of Infectious Diseases 2016, 56: 185-189. PMID: 28007660, PMCID: PMC5576040, DOI: 10.1016/j.ijid.2016.12.010.Peer-Reviewed Original ResearchConceptsSecond-line drug susceptibility testingRifampin-resistant tuberculosisDrug susceptibility testingSecond-line drug resistanceDrug resistanceSusceptibility testingHigh-burden settingsSecond-line drugsDrug-resistant tuberculosisEffective regimensTreatment failureTreatment outcomesSmall incremental costEpidemiologic benefitsResistance amplificationPatientsTuberculosisIncremental costMost settingsWidespread implementationSettingRegimensPrevalenceAssessing Local Risk of Rifampicin-Resistant Tuberculosis in KwaZulu-Natal, South Africa Using Lot Quality Assurance Sampling
Heidebrecht CL, Podewils LJ, Pym A, Mthiyane T, Cohen T. Assessing Local Risk of Rifampicin-Resistant Tuberculosis in KwaZulu-Natal, South Africa Using Lot Quality Assurance Sampling. PLOS ONE 2016, 11: e0153143. PMID: 27050561, PMCID: PMC4822784, DOI: 10.1371/journal.pone.0153143.Peer-Reviewed Original ResearchConceptsIncident TB casesTB casesResistant TBDrug-resistant TB casesRifampicin-resistant tuberculosisMultidrug-resistant tuberculosisDrug susceptibility testingRIF-resistant TBLot Quality Assurance SamplingQuality assurance samplingResistant diseaseHigh burdenRIF resistanceKwaZulu-NatalSusceptibility testingHigh-risk areasTuberculosisRiskGreater proportionBurdenTBDiseaseGeographic heterogeneityCasesRifampicin
2014
Impact and cost-effectiveness of current and future tuberculosis diagnostics: the contribution of modelling
Dowdy DW, Houben R, Cohen T, Pai M, Cobelens F, Vassall A, Menzies NA, Gomez GB, Langley I, Squire SB, White R, for the TB MAC meeting participants. Impact and cost-effectiveness of current and future tuberculosis diagnostics: the contribution of modelling. The International Journal Of Tuberculosis And Lung Disease 2014, 18: 1012-1018. PMID: 25189546, PMCID: PMC4436823, DOI: 10.5588/ijtld.13.0851.Peer-Reviewed Original Research
2012
Linking Surveillance with Action against Drug-Resistant Tuberculosis
Cohen T, Manjourides J, Hedt-Gauthier B. Linking Surveillance with Action against Drug-Resistant Tuberculosis. American Journal Of Respiratory And Critical Care Medicine 2012, 186: 399-401. PMID: 22592806, PMCID: PMC3443807, DOI: 10.1164/rccm.201203-0394pp.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisForms of TBDrug-resistant TBManagement of patientsDrug-resistant tuberculosisSecond-line drugsEffective public health responseDrug susceptibility testingPublic health responseQuality-assured treatmentMDRTB treatmentIncident casesHigh burdenProgrammatic dataHealth responseDrug resistanceSusceptibility testingImproved surveillance methodsPopulation subgroupsSurveillance methodsSurveillance activitiesTuberculosisClear roleTreatmentRecent global estimatesUse of Spatial Information to Predict Multidrug Resistance in Tuberculosis Patients, Peru - Volume 18, Number 5—May 2012 - Emerging Infectious Diseases journal - CDC
Lin HH, Shin SS, Contreras C, Asencios L, Paciorek CJ, Cohen T. Use of Spatial Information to Predict Multidrug Resistance in Tuberculosis Patients, Peru - Volume 18, Number 5—May 2012 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2012, 18: 811-813. PMID: 22516236, PMCID: PMC3358052, DOI: 10.3201/eid1805.111467.Peer-Reviewed Original Research
2010
Assessing spatiotemporal patterns of multidrug-resistant and drug-sensitive tuberculosis in a South American setting
LIN H, SHIN S, BLAYA JA, ZHANG Z, CEGIELSKI P, CONTRERAS C, ASENCIOS L, BONILLA C, BAYONA J, PACIOREK CJ, COHEN T. Assessing spatiotemporal patterns of multidrug-resistant and drug-sensitive tuberculosis in a South American setting. Epidemiology And Infection 2010, 139: 1784-1793. PMID: 21205434, PMCID: PMC3153578, DOI: 10.1017/s0950268810002797.Peer-Reviewed Original ResearchConceptsTB casesMDR diseaseMultidrug-resistant tuberculosis (MDR-TB) casesDrug-sensitive tuberculosisDrug-resistant diseaseDrug susceptibility testingMDR-TBMDR casesTuberculosis casesIncident casesSubgroup analysisInfection controlK statisticInfectious durationAppearance of resistanceDistricts of LimaSusceptibility testingDiseasePatientsTBUrban settingsCasesTuberculosisSettingMDR